Genetic and clinical insights into acute kidney injury in maturity‑onset diabetes of the young caused by the <em>ABCC8</em> c.2500C&gt;T mutation: Potential risk factors associated with SGLT2 inhibitors

Zou,Jing; Chen,Xiang; Yu,Hong-Ping; Chen,Ying; He,Kai-Ying; Ruan,Dan-Dan; Zhu,Juan; Chen,Qian; Zhang,Jian-Hui; Zhang,Li; Gan,Yu-Mian; Gao,Mei-Zhu; Chen,Li; Liang,Ji-Xing; Wu,Tian-Min; Liao,Li-Sheng; Luo,Jie-Wei

doi:10.3892/etm.2025.12914

Genetic and clinical insights into acute kidney injury in maturity‑onset diabetes of the young caused by the ABCC8 c.2500C>T mutation: Potential risk factors associated with SGLT2 inhibitors

Authors:
- Jing Zou
- Xiang Chen
- Hong-Ping Yu
- Ying Chen
- Kai-Ying He
- Dan-Dan Ruan
- Juan Zhu
- Qian Chen
- Jian-Hui Zhang
- Li Zhang
- Yu-Mian Gan
- Mei-Zhu Gao
- Li Chen
- Ji-Xing Liang
- Tian-Min Wu
- Li-Sheng Liao
- Jie-Wei Luo
View Affiliations

Affiliations: Department of Traditional Chinese Medicine and Neurology, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian 350001, P.R. China, The First Clinical Medical College, Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian 350122, P.R. China, Department of Endocrinology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian 350001, P.R. China, Department of Traditional Chinese Medicine, The First Affiliated Hospital, Fujian Medical University, Fuzhou, Fujian 350005, P.R. China, Department of Hematology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian 350001, P.R. China
Published online on: June 26, 2025 https://doi.org/10.3892/etm.2025.12914
Article Number: 164
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mature‑onset diabetes of the young (MODY) is an autosomal dominant genetic disease that is typically diagnosed during childhood or early adolescence. The primary pathogenesis of MODY involves gene mutations that impair insulin synthesis and/or secretion by islet β cells, rendering the condition independent of insulin resistance. A family with the MODY‑12 phenotype caused by an ATP‑binding cassette subfamily C member 8 (ABCC8) gene mutation was investigated in the present study. Clinical data were collected from all family members, and second‑generation gene sequencing and Sanger sequencing were performed. The suspected pathogenic mutation was validated by Sanger sequencing, and the three‑dimensional structure of the pathogenic variant protein was predicted and simulated using the Swiss‑Model platform. Five individuals with MODY‑12, including the proband, were identified in this family. Second‑generation gene sequencing confirmed that all family members carried the ABCC8 c.2500C>T (p.Arg834Cys) mutation. Structural modeling revealed that the replacement of arginine at position 834 in the wild‑type protein with cysteine results in the formation of an additional hydrogen bond with the surrounding amino acids. In addition, the ABCC8 c.2500C>T carriers in this family experienced recurrent diabetic ketoacidosis and acute kidney involvement (AKI) phenotypes, and all patients had a history of sodium‑glucose transporter 2 inhibitor (SGLT2i) use. We hypothesize that AKI in these patients may be pseudo‑AKI associated with the use of SGLT2is. However, the proband exhibited symptoms indicative of rapidly progressing diabetic nephropathy. This study demonstrates that clinicians managing patients with MODY should be aware of the risk of acute and serious complications, particularly as SGLT2i may induce pseudo‑AKI, which could ultimately compromise patients' long‑term renal prognosis.

View Figures

View References

1	Aarthy R, Aston-Mourney K, Mikocka-Walus A, Radha V, Amutha A, Anjana RM, Unnikrishnan R and Mohan V: Clinical features, complications and treatment of rarer forms of maturity-onset diabetes of the young (MODY) - A review. J Diabetes Complications. 35(107640)2021.PubMed/NCBI View Article : Google Scholar
2	Li J, Wang X, Mao H, Wen L, Deng A, Li Y, Zhang H and Liu C: Precision therapy for three Chinese families with maturity-onset diabetes of the young (MODY12). Front Endocrinol (Lausanne). 13(858096)2022.PubMed/NCBI View Article : Google Scholar
3	Yahaya TO and Ufuoma SB: Genetics and pathophysiology of maturity-onset diabetes of the young (MODY): A review of current trends. Oman Med J. 35(e126)2020.PubMed/NCBI View Article : Google Scholar
4	Fajans SS and Bell GI: MODY: History, genetics, pathophysiology, and clinical decision making. Diabetes Care. 34:1878–1884. 2011.PubMed/NCBI View Article : Google Scholar
5	Shepherd M, Shields B, Hammersley S, Hudson M, McDonald TJ, Colclough K, Oram RA, Knight B, Hyde C, Cox J, et al: Systematic population screening, using biomarkers and genetic testing, identifies 2.5% of the U.K. pediatric diabetes population with monogenic diabetes. Diabetes Care. 39:1879–1888. 2016.PubMed/NCBI View Article : Google Scholar
6	Irgens HU, Molnes J, Johansson BB, Ringdal M, Skrivarhaug T, Undlien DE, Søvik O, Joner G, Molven A and Njølstad PR: Prevalence of monogenic diabetes in the population-based norwegian childhood diabetes registry. Diabetologia. 56:1512–1519. 2013.PubMed/NCBI View Article : Google Scholar
7	Tattersall RB and Fajans SS: A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes. 24:44–53. 1975.PubMed/NCBI View Article : Google Scholar
8	Kant R, Davis A and Verma V: Maturity-onset diabetes of the young: Rapid evidence review. Am Fam Physician. 105:162–167. 2022.PubMed/NCBI
9	Ovsyannikova AK, Rymar OD, Shakhtshneider EV, Voropaeva EN, Ivanoshchuk DE and Voevoda MI: MODY in Siberia-molecular genetics and clinical characteristics. Diabetes Mellitus. 20:5–12. 2017.(In Russ).
10	Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al: Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology. Genet Med. 17:405–424. 2015.PubMed/NCBI View Article : Google Scholar
11	Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC and Ferrin TE: UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem. 25:1605–1612. 2004.PubMed/NCBI View Article : Google Scholar
12	American Diabetes Association. 6. Glycemic targets: Standards of medical care in diabetes-2019. Diabetes Care. 42 (Suppl 1):S61–S70. 2019.PubMed/NCBI View Article : Google Scholar
13	Ohta Y, Tanizawa Y, Inoue H, Hosaka T, Ueda K, Matsutani A, Repunte VP, Yamada M, Kurachi Y, Bryan J, et al: Identification and functional analysis of sulfonylurea receptor 1 variants in Japanese patients with NIDDM. Diabetes. 47:476–481. 1998.PubMed/NCBI View Article : Google Scholar
14	Olson TM and Terzic A: Human K(ATP) channelopathies: Diseases of metabolic homeostasis. Pflugers Arch. 460:295–306. 2010.PubMed/NCBI View Article : Google Scholar
15	Fukuda Y, Aguilar-Bryan L, Vaxillaire M, Dechaume A, Wang Y, Dean M, Moitra K, Bryan J and Schuetz JD: Conserved intramolecular disulfide bond is critical to trafficking and fate of ATP-binding cassette (ABC) transporters ABCB6 and sulfonylurea receptor 1 (SUR1)/ABCC8. J Biol Chem. 286:8481–8492. 2011.PubMed/NCBI View Article : Google Scholar
16	De Franco E, Saint-Martin C, Brusgaard K, Knight Johnson AE, Aguilar-Bryan L, Bowman P, Arnoux JB, Larsen AR, Sanyoura M, Greeley SAW, et al: Update of variants identified in the pancreatic β-cell K(ATP) channel genes KCNJ11 and ABCC8 in individuals with congenital hyperinsulinism and diabetes. Hum Mutat. 41:884–905. 2020.PubMed/NCBI View Article : Google Scholar
17	Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M and Froguel P: Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med. 355:456–466. 2006.PubMed/NCBI View Article : Google Scholar
18	Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S and Hattersley AT: Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care. 31:204–209. 2008.PubMed/NCBI View Article : Google Scholar
19	Tarasov AI, Nicolson TJ, Riveline JP, Taneja TK, Baldwin SA, Baldwin JM, Charpentier G, Gautier JF, Froguel P, Vaxillaire M and Rutter GA: A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K+ channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults. Diabetes. 57:1595–1604. 2008.PubMed/NCBI View Article : Google Scholar
20	Proks P, Girard C and Ashcroft FM: Functional effects of KCNJ11 mutations causing neonatal diabetes: Enhanced activation by MgATP. Hum Mol Genet. 14:2717–2726. 2005.PubMed/NCBI View Article : Google Scholar
21	Yan FF, Lin YW, MacMullen C, Ganguly A, Stanley CA and Shyng SL: Congenital hyperinsulinism associated ABCC8 mutations that cause defective trafficking of ATP-sensitive K+ channels: Identification and rescue. Diabetes. 56:2339–2348. 2007.PubMed/NCBI View Article : Google Scholar
22	de Wet H, Rees MG, Shimomura K, Aittoniemi J, Patch AM, Flanagan SE, Ellard S, Hattersley AT, Sansom MS and Ashcroft FM: Increased ATPase activity produced by mutations at arginine-1380 in nucleotide-binding domain 2 of ABCC8 causes neonatal diabetes. Proc Natl Acad Sci USA. 104:18988–18992. 2007.PubMed/NCBI View Article : Google Scholar
23	Ashcroft FM: ATP-sensitive potassium channelopathies: Focus on insulin secretion. J Clin Invest. 115:2047–2058. 2005.PubMed/NCBI View Article : Google Scholar
24	Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 373:2117–2128. 2015.PubMed/NCBI View Article : Google Scholar
25	Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapas A, Wexler DJ and Buse JB: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 41:2669–2701. 2018.PubMed/NCBI View Article : Google Scholar
26	Kaze AD, Zhuo M, Kim SC, Patorno E and Paik JM: Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: A meta-analysis. Cardiovasc Diabetol. 21(47)2022.PubMed/NCBI View Article : Google Scholar
27	DeFronzo RA, Norton L and Abdul-Ghani M: Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 13:11–26. 2017.PubMed/NCBI View Article : Google Scholar
28	Hahn K, Ejaz AA, Kanbay M, Lanaspa MA and Johnson RJ: Acute kidney injury from SGLT2 inhibitors: Potential mechanisms. Nat Rev Nephrol. 12:711–712. 2016.PubMed/NCBI View Article : Google Scholar
29	Myers SR, Glaser NS, Trainor JL, Nigrovic LE, Garro A, Tzimenatos L, Quayle KS, Kwok MY, Rewers A, Stoner MJ, et al: Frequency and risk factors of acute kidney injury during diabetic ketoacidosis in children and association with neurocognitive outcomes. JAMA Netw Open. 3(e2025481)2020.PubMed/NCBI View Article : Google Scholar
30	Yang H, Yang L, Jardine MJ, Arnott C, Neuen BL, Xu K, Zhao X, Qian D, Cui B, Qiu Y, et al: The association between sodium-glucose cotransporter 2 inhibitors and contrast-associated acute kidney injury in patients with type 2 diabetes undergoing angiography: A propensity-matched study. Eur J Med Res. 29(621)2024.PubMed/NCBI View Article : Google Scholar
31	Chang YK, Choi H, Jeong JY, Na KR, Lee KW, Lim BJ and Choi DE: Dapagliflozin, SGLT2 inhibitor, attenuates renal ischemia-reperfusion injury. PLoS One. 11(e0158810)2016.PubMed/NCBI View Article : Google Scholar
32	Heyman SN, Rosenberger C, Rosen S and Khamaisi M: Why is diabetes mellitus a risk factor for contrast-induced nephropathy? Biomed Res Int. 2013(123589)2013.PubMed/NCBI View Article : Google Scholar
33	Errabelli P, Lathiya M and Singh D: Case report: A case of pseudo-acute kidney injury due to cyclin-dependent kinase inhibitor. Front Nephrol. 4(1389562)2024.PubMed/NCBI View Article : Google Scholar
34	Huang SK, Huang CY, Lin CH, Cheng BW, Chiang YT, Lee YC, Yeh SN, Chan CI, Chua WK, Lee YJ and Ting WH: Acute kidney injury is a common complication in children and adolescents hospitalized for diabetic ketoacidosis. PLoS One. 15(e0239160)2020.PubMed/NCBI View Article : Google Scholar
35	Damman K and Testani JM: The kidney in heart failure: An update. Eur Heart J. 36:1437–1444. 2015.PubMed/NCBI View Article : Google Scholar
36	Drozdzal S, Lechowicz K, Szostak B, Rosik J, Kotfis K, Machoy-Mokrzyńska A, Białecka M, Ciechanowski K and Gawrońska-Szklarz B: Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature. Pharmacol Res Perspect. 9(e00817)2021.PubMed/NCBI View Article : Google Scholar
37	Deng K, Pei M, Li B, Yang N, Wang Z, Wan X, Zhong Z, Yang Z and Chen Y: Signal pathways involved in contrast-induced acute kidney injury. Front Physiol 2024; 15: 1490725.